Asundexian

The OCEANIC-STROKE randomized trial demonstrates that adding asundexian to antiplatelet therapy reduces ischemic stroke without a significant rise in major bleeding, though it increases lower gastrointestinal bleeding in patients with noncardioembolic ischemic stroke or high-risk TIA.